Pipeline PR & Com Resources Scroll to explore Scroll back top Domain’s Resources Our most up-to-date material only a click away A pan group III mGluR PAM candidate ready to enter pre-IND studies By targeting not only mGluR4 but also mGluR7 and 8, and by exhibiting an improved oral PK profile, DT095435 is positioned as a second generation compound that should succeed in reaching clinical efficacy where Foliglurax narrowly failed. Download file A reliable real time pharmacological platform dedicated to the study of ICP co-receptors This poster presents bioSens-All®️, a powerful and versatile pharmacological platform which is highly adaptable for hot topic targets such as Immune Checkpoint targets (Inhibitory & Stimulatory Immune Checkpoints). Download file Use of novel ebBRET biosensors for comprehensive signaling profiling of 100 therapeutically relevant human GPCRs Here, we describe a novel suite of enhanced bystander bioluminescence resonance energy transfer (ebBRET)-based biosensors that were used to define the signaling profiles of 100 therapeutically relevant human GPCRs in response to endogenous (or prototypical) ligands. Download file A high value pharmacological platform dedicated to the real time study of Stimulatory immune checkpoint signaling pathways We present here several innovative BRET assays dedicated to inhibitory and stimulatory ICPs (PD-1, CTLA-4, 4-1BB), and developed by us. The ICP platform set up here shows good accuracy & robustness and represents a solid & reliable technology for ICP dedicated drug discovery. Download file A pharmacological platform for the real time study of ICP signaling pathways This poster presents the last generation of our proprietary platform bioSens-All®️ which is dedicated to the identification and characterization of immune checkpoint inhibitors. Download file DT095597 a New NPFFR1 Antagonist Devoid of Addictive Properties to Fight Opioid Crisis This poster presents the characterization of a proprietary NPFF receptor antagonist as a game-changer and a promising therapeutic strategy to fight the current opioid crisis. Download file Decrypting EGFR signaling with BRET biosensors : A novel approach to study RTK mutations and the effects of inhibitors This poster illustrates a valuable BRET-based platform used to characterize RTK candidates regarding constitutive activity, real-time kinetics or impact of RTK mutations on signalling pathways. Download file “GPCR-ome” modulation upon PD1 / PDL1 axis blockade co-authored with Explicyte, Bordeaux, France & Institut Bergonié, Bordeaux, France, this poster discloses an in-depth GPCR expression analysis from tumor microenvironment to dissect out mechanisms of resistance to immune checkpoint inhibitors. Download file DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best-in-class properties This poster presents the complete characterization of Domain drug candidate benchmarked to EP4 antagonist molecules currently in the clinic and demonstrating a best-in-class potential. Download file DT095435: A novel “pan” group III metabotropic glutamate receptor positive allosteric modulator for Parkinson’s disease This poster presents the profiling of DT095435, our pan group III mGluR PAM development candidate, as a potential new anti-dyskinetic treatment for Parkinson's disease. Download file Creation of a large-spectrum GPCR biosensor for functional in vitro safety and systems pharmacology analysis This study served as a validation of the utility of the Gz/G15 large-spectrum biosensor for safety and systems pharmacology profiling. Moreover, our results support the use of this cell-based functional assay in high throughput receptor deorphanization and functional screening programs. Download file GPCRs in oncology and immuno-oncology : The IRIC's virtual symposium 2021 [VIDEO] Chaired by IRIC's CEO Michel Bouvier, this symposium will showcase some of the latest discoveries & techniques leveraging the potential of GPCRs in oncology and immuno-oncology. Leading experts will share findings from world-class academic & private research on GPCRs in those crucial fields. Download file Opportunities Partnering Opportunities Pipeline Partnering Opportunities Resources Careers Contact us 77/100 2021 #Discovermorethanyouthink Strasbourg - Illkirch Domain Therapeutics SA Bioparc 1 - 850 Boulevard Sébastien Brant 67400 Strasbourg - Illkirch - France https://www.domaintherapeutics.com/ Montreal Domain Therapeutics NA Inc. Neomed Institute - 7171 Frédérick Banting H4S 1Z9 Montreal - Canada https://www.domaintherapeutics.ca/ © 2021 Domain Therapeutics - All rights reserved Privacy Legal notices RSS Axeptio consent